IYUZEH™ has demonstrated tolerability

Chart icon

Learn about treatment emergent adverse events (TEAEs).
SEE THE DATA

INCIDENCE OF OCULAR ADVERSE EVENTS (AEs)

In clinical trials conducted with IYUZEH™ (latanoprost ophthalmic solution) 0.005% comparing it to XALATAN®, the most frequently reported ocular adverse reactions were conjunctival hyperemia (34% for IYUZEH vs 37% for XALATAN) and eye irritation (19% for IYUZEH vs 31% for XALATAN).1,2

Chart comparing Iyuzeh and Xalatan most frequently reported ocular adverse reactions in clinical trials.

TREATMENT EMERGENT ADVERSE EVENTS (TEAEs) IN THE US PHASE III TRIAL

IYUZEH (n=165) was well-tolerated with a lower incidence of overall ocular TEAEs compared to XALATAN (n=169) in the US phase III clinical trial.2,3,*

  • The most frequently reported TEAEs were instillation site pain, conjunctival hyperemia, blepharitis, instillation site pruritus, and punctate keratitis3

*TEAEs were calculated with a narrower definition of occurrence by investigators in this study compared to those reported in the PI, which contains ocular TEAEs reported by ≥1% of subjects receiving IYUZEH, accounting for the discrepancy in values calculated.

XALATAN is a registered trademark of Pfizer PFE Holdings 4 LLC, a Viatris Company.

Incidence of Reported Ocular TEAEs in US IYUZEH Phase III Trial (Safety Population)2

Chart comparing Iyuzeh and Xalatan reported ocular treatment-emergent adverse events in the Iyuzeh phase 3 US clinical trial.

Hear what your colleagues are saying about IYUZEH

Challenges of any preserved ophthalmic formulation include tolerability, worsening of ocular surface disease, and that can result in compliance issues. And so anything we can do to afford a patient the ability to stay on the drug is critical in the long-term strategic success in keeping people’s vision.

Jason M. Bacharach, MD

Dr. Bacharach is a paid consultant of Thea Pharma Inc.

Visit our Video Library to Hear Why Eye Care Professionals are Choosing IYUZEH

Things your patients may not say, but could be thinking

Ivan,† Tired of Getting a Different Generic with Every Refill

Every time Ivan picks up his generic IOP-lowering medication, it is from a different generic manufacturer. Ivan is looking for a branded medication that gives him a consistent product and experience each refill.

With a prescription for IYUZEH, he now has the peace of mind of always knowing what to expect each month – the first and only preservative-free latanoprost.

†Patient portrayal. Not an actual patient.

Ivan is a patient tired of getting a different generic with every refill.
Ivan is a patient tired of getting a different generic with every refill.

Every time Ivan picks up his generic IOP-lowering medication, it is from a different generic manufacturer. Ivan is looking for a branded medication that gives him a consistent product and experience each refill.

With a prescription for IYUZEH, he now has the peace of mind of always knowing what to expect each month – the first and only preservative-free latanoprost.

†Patient portrayal. Not an actual patient.